Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948831 · ClinicalTrials.gov registry record
Osteocel® Plus in Anterior Lumbar Interbody Fusion (ALIF)
A clinical trial of Degenerative Disc Disease Lumbar, sponsored by NuVasive.
- Completed
- Registry status
- 51
- Enrollment target
- 7
- Study locations
NCT00948831: Completed study of Degenerative Disc Disease Lumbar, sponsored by NuVasive.
NCT00948831 is a study of Degenerative Disc Disease Lumbar that has completed, run by NuVasive. The registered enrollment target is 51 participants. The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00948831, a study of Degenerative Disc Disease Lumbar, has completed, sponsored by NuVasive.
- COMPLETED
- Registry status
- 51 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is being conducted to determine the percentage of patients with solid spinal fusions after being treated with Osteocel Plus in an ALIF procedure. Due to the unique processing conditions, Osteocel Plus retains a high concentration of stem cells in conjunction with the allograft bone matrix, so it is hypothesized that the fusion rate with Osteocel Plus will be comparable to published data for autograft. The Osteocel product family has already been used in approximately 15,000 cases worldwide.
Conditions Studied
Interventions
- BIOLOGICAL Osteocel Plus
Study Locations (7)
Indiana
- OrthoIndy, Indiana Orthopedic Hospital - Indianapolis
- Indiana Spine Group, St. Joseph's Hospital - Kokomo
California
- University of California at San Francisco - San Francisco
Minnesota
- Twin Cities Orthopaedics, University of Minnesota Medical Center - Edina
Montana
- Ortho Montana - Billings
Ohio
- Cleveland Clinic - Cleveland
Texas
- Central Texas Spine Institute, Northwest Hills Surgical Hospital - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-10 |
What the finished NCT00948831 record still lists
NCT00948831 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 51 participants, a relatively small participant target.
The record links to 1 condition, with Degenerative Disc Disease Lumbar appearing as the primary indexed condition, and to 1 intervention - of which Osteocel Plus is the first listed.
NCT00948831 lists 7 locations in 6 states (Indiana, California, Minnesota).
Frequently Asked Questions
What is clinical trial NCT00948831 about?
NCT00948831 is a clinical study titled "Osteocel® Plus in Anterior Lumbar Interbody Fusion (ALIF)". This study is being conducted to determine the percentage of patients with solid spinal fusions after being treated with Osteocel Plus in an ALIF procedure. Due to the unique processing conditions, Osteocel Plus retains a high concentration of stem cells in conjunction with the allograft bone matrix...
What is the current status of trial NCT00948831?
This trial is currently completed. The enrollment target is 51 participants. The study started on 2009-04. Estimated completion is 2012-10.
What conditions does trial NCT00948831 study?
This clinical trial studies the following conditions: Degenerative Disc Disease Lumbar.
What interventions are being tested in trial NCT00948831?
The interventions under investigation include: Osteocel Plus (BIOLOGICAL).
Who is sponsoring clinical trial NCT00948831?
This trial is sponsored by NuVasive, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00948831 being conducted?
This trial has 7 study locations across California, Indiana, Minnesota, Montana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Degenerative Disc Disease Lumbar
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia